Eris Lifesciences Ltd (NSE:ERIS)
₹ 1008.8 -14.45 (-1.41%) Market Cap: 137.34 Bil Enterprise Value: 151.12 Bil PE Ratio: 35.06 PB Ratio: 5.31 GF Score: 97/100

Q1 2024 Eris Lifesciences Ltd Earnings Call Transcript

Aug 07, 2023 / 10:30AM GMT
Release Date Price: ₹828.2 (+3.45%)
Operator

Ladies and gentlemen, good day and welcome to the Q1 FY '24 Earnings Conference Call of Eris Lifesciences Limited.

We have with us on the call today Mr. Amit Bakshi, Chairman and Managing Director; and Mr. V. Krishnakumar, Chief Operating Officer and Executive Director. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you. And over to you, sir.

Krishnakumar Vaidyanathan
Eris Lifesciences Limited - Executive Director & COO

Thank you. Good afternoon, and welcome to our conference call for the first quarter of FY '24. Our branded formulations business accounts for 97% of our consolidated revenue, and this includes the standalone entity, Eris Lifesciences, it includes Oaknet Healthcare, our insulin business, Eris MJ, Eris Therapeutics, which houses our Gujarat facility commercialized in March and Aprica. This segment excludes EHPL.

The operating revenue for our branded formulations

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot